EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive

Myeloma Patients Europe has participating along with 13 European Patient organisations in the statement calling on European institutions to adopt appropriate measures to incorporate meaningful involvement of patients in EU cooperation on health technology assessment (HTA).

Patients and their organisations are convinced that changes need to be made to the legislation before it is adopted to guarantee an adequate involvement of patients in all HTA activities (joint consultations, early dialogues, scoping and assessments), which is essential to help HTA assessors determine the relative efficacy and safety of health technologies.

The joint statement contents four points explaining those aspects in which patient involvement can make a difference in the HTA process. Read the full document here.







Recent news

» Horizon2020 CARAMBA Myeloma Pipeline information sheet now available in five languages

» The FDA approves the first anti-BCMA CAR-T Cell Therapy for myeloma, idecabtagene vicleucel (Abecma)

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.